Ephedrine
As of the edition of 20 October 2026, Ephedrine is a small molecule: marketed, first approved in 1979 (CH); acts on ADRA1A, ADRA1B and ADRA1D and 6 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Small molecule
- Brand name
- Akovaz
- First approved
- 8 October 1979 (CH)
- Approvals on record
- 17 in 4 regions
- Holder of the most recent approval
- Baxter Healthcare; 10 holders in all
- Withdrawn from market
- 1 January 2005 (in some regions)
- Registered trials
- 51, 2 stopped early
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Nervous system; Nutrition and metabolism; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
9 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product9 company-target rows are on route B because of Ephedrine.
See the 9 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
| ADRB1 | Beta-1 adrenergic receptor | P08588 |
| ADRA2A | Alpha-2A adrenergic receptor | P08913 |
| ADRB3 | Beta-3 adrenergic receptor | P13945 |
| ADRA2B | Alpha-2B adrenergic receptor | P18089 |
| ADRA2C | Alpha-2C adrenergic receptor | P18825 |
| ADRA1D | Alpha-1D adrenergic receptor | P25100 |
| ADRA1A | Alpha-1A adrenergic receptor | P35348 |
| ADRA1B | Alpha-1B adrenergic receptor | P35368 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 28 | 16 | 4 | 1 |
| Phase 2 | 4 | 3 | 0 | 0 |
| Phase 3 | 7 | 4 | 0 | 1 |
| Phase 4 | 12 | 8 | 2 | 0 |
| All trials | 51 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Akorn | Later holder | 2017 to now |
| Nexus Pharmaceuticals | Later holder | 2020 to now |
| Nevakar | Later holder | 2020 to now |
| Exela Pharma Sciences | Acquired holder | 2020 to now |
| Eton Pharmaceuticals | Later holder | 2021 to now |
| Dr. Reddy's | Acquired holder | 2022 to now |
| Renew Pharmaceuticals | Acquired holder | 2023 to now |
| Baxter Healthcare | Applicant | 2023 to now |
| Ph Health | Acquired holder | 2025 to now |